Body

RYBREVANT® Website

RYBREVANT.com - This website contains additional information about treatment with RYBREVANT®. On this website, you can also get helpful information about your condition.

 

Personalized Support

Schedule a call with a Care Navigator for one-on-one support

 

JanssenCompass.com - Receive free, personalized resources to help you get started on treatment. A dedicated Janssen Compass® Care Navigator can help you find options that may lower your medication costs and personalized educational resources to help you feel confident on your RYBREVANT® therapy.

Janssen Compass® is limited to education about your Janssen therapy, its administration, and/or your disease. It is intended to supplement your understanding of your therapy and is not intended to provide medical advice, replace a treatment plan from your doctor or nurse, or serve as a reason for you to start or stay on this medication.

 

 

Cost Support

Janssen CarePath Savings Program Overview [PDF] - Provides information on the Janssen CarePath Savings Program for RYBREVANT® and eligibility requirements for enrolling in the program.

Janssen CarePath Savings Program Patient Assignment of Benefits [DOCX] - Allows you to authorize your provider to receive your Janssen CarePath Savings Program rebate on your medication on your behalf.

Patient Affordability Options for RYBREVANT® [PDF] - Gives information on options that can make your treatment more affordable.

 

Coverage

Health Insurance Open Enrollment Guide [PDF] - Even if you keep the same health plan, your benefits can change. This guide can help you review your coverage and make changes if needed during the open enrollment period so you can stay on treatment in the new benefit period. Health Insurance Open Enrollment Guide [PDF] (en español).

Medicare Resource Guide [PDF] - Provides information on sources for cost support that may be available to patients enrolled in Medicare. Medicare Resource Guide [PDF] (en español).

Medicare Part D Resource for Patients [PDF] - Helps you understand the 4 phases of coverage (Deductible, Initial Coverage, Coverage Gap, and Catastrophic Coverage), and when you will enter the Coverage Gap (formerly known as the Donut Hole). Medicare Part D Resource for Patients [PDF] (en español).

Medicare Low-Income Subsidy (LIS) Brochure [PDF] - Offers information about extra help with prescription drug costs that is available to low-income residents of the United States enrolled in Medicare Prescription Drug Plans.

 

Back

IMPORTANT SAFETY INFORMATION
  • Minimize
  • Expand
  • Full Screen
  • Return to Website

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults:

  • in combination with carboplatin and pemetrexed as a first-line treatment for non-small cell lung cancer (NSCLC) that:
    • has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
    • has a certain abnormal epidermal growth factor receptor “EGFR” gene(s)
  • alone for the treatment of non-small cell lung cancer (NSCLC) that:
    • has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
    • has a certain abnormal EGFR gene(s), and whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT® is right for you. It is not known if RYBREVANT® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT®, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of lung or breathing problems.
  • are pregnant or plan to become pregnant. RYBREVANT® can harm your unborn baby.

Females who are able to become pregnant:

  • Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT®.
  • You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
  • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT®.
  • are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® passes into your breast milk. Do not breastfeed during treatment and for 3 months after your final dose of RYBREVANT®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive RYBREVANT®?

  • RYBREVANT® will be given to you by your healthcare provider by intravenous infusion into your vein.
  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
  • Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of infusion-related reactions.
  • RYBREVANT® may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What should I avoid while receiving RYBREVANT®?

RYBREVANT® can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT®. Wear protective clothing and use sunscreen during treatment with RYBREVANT®.

What are the possible side effects of RYBREVANT®?

RYBREVANT® may cause serious side effects, including:

  • infusion-related reactions. Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:
  • shortness of breath
  • fever
  • chills
  • nausea
  • flushing
  • chest discomfort
  • lightheadedness
  • vomiting
  • lung problems. RYBREVANT® may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
  • skin problems. RYBREVANT® may cause rash, itching, and dry skin. You may use alcohol-free moisturizing cream for dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT®. See “What should I avoid while receiving RYBREVANT®?”
  • eye problems. RYBREVANT® may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
  • eye pain
  • dry eyes
  • eye redness
  • blurred vision
  • changes in vision
  • itchy eyes
  • excessive tearing
  • sensitivity to light

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems during treatment with RYBREVANT®. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT® in combination with carboplatin and pemetrexed include:

  • rash
  • infected skin around the nail
  • sores in the mouth
  • infusion-related reactions
  • feeling very tired
  • swelling of hands, ankles, feet, face, or all of your body
  • constipation
  • decreased appetite
  • nausea
  • COVID-19
  • diarrhea
  • vomiting
  • changes in certain blood tests

The most common side effects of RYBREVANT® when given alone:

  • rash
  • infusion-related reactions
  • infected skin around the nail
  • muscle and joint pain
  • shortness of breath
  • nausea
  • feeling very tired
  • swelling of hands, ankles, feet, face, or all of your body
  • sores in the mouth
  • cough
  • constipation
  • vomiting
  • changes in certain blood tests

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® if you have serious side effects.

These are not all of the possible side effects of RYBREVANT®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

General information about the safe and effective use of RYBREVANT®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about RYBREVANT® that is written for health professionals.

Please read full Prescribing Information for RYBREVANT®.

cp-213277v4